Literature DB >> 18954903

Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Rebecca J Chan1, Todd Cooper, Christian P Kratz, Brian Weiss, Mignon L Loh.   

Abstract

Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative disorder characterized by the overproduction of myelomonocytic cells. JMML incidence approaches 1.2/million persons in the United States (Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995). Although rare, JMML is innately informative as the molecular genetics of this disease implicates hyperactive Ras as an essential initiating event. Given that Ras is one of the most frequently mutated oncogenes in human cancer, findings from this disease are applicable to more genetically diverse and complex adult leukemias. The JMML Foundation (www.jmmlfoundation.org) was founded by parent advocates dedicated to finding a cure for this disease. They work to bring investigators together in a collaborative manner. This article summarizes key presentations from The Second International JMML Symposium, on 7-8 December 2007 in Atlanta, GA. A list of all participants is in Supplementary Table.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18954903      PMCID： PMC2692866          DOI： 10.1016/j.leukres.2008.08.022

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  55 in total

1.  Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia.

Authors:  A Yoshimi; M Mohamed; M Bierings; C Urban; E Korthof; M Zecca; K-W Sykora; U Duffner; M Trebo; S Matthes-Martin; P Sedlacek; T Klingebiel; P Lang; M Führer; A Claviez; W Wössmann; A Pession; J Arvidson; A S O'Marcaigh; M M van den Heuvel-Eibrink; J Starý; H Hasle; P Nöllke; F Locatelli; C M Niemeyer
Journal:  Leukemia       Date:  2007-02-01       Impact factor: 11.528

2.  Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

Authors:  Pablo Rodriguez-Viciana; Osamu Tetsu; William E Tidyman; Anne L Estep; Brenda A Conger; Molly Santa Cruz; Frank McCormick; Katherine A Rauen
Journal:  Science       Date:  2006-01-26       Impact factor: 47.728

3.  Germline gain-of-function mutations in SOS1 cause Noonan syndrome.

Authors:  Amy E Roberts; Toshiyuki Araki; Kenneth D Swanson; Kate T Montgomery; Taryn A Schiripo; Victoria A Joshi; Li Li; Yosuf Yassin; Alex M Tamburino; Benjamin G Neel; Raju S Kucherlapati
Journal:  Nat Genet       Date:  2006-12-03       Impact factor: 38.330

4.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

Authors:  Kazuyuki Matsuda; Akira Shimada; Nao Yoshida; Atsushi Ogawa; Akihiro Watanabe; Shuhei Yajima; Susumu Iizuka; Kazutoshi Koike; Fumio Yanai; Keiichiro Kawasaki; Masakatsu Yanagimachi; Akira Kikuchi; Yoshitoshi Ohtsuka; Eiko Hidaka; Kazuyoshi Yamauchi; Miyuki Tanaka; Ryu Yanagisawa; Yozo Nakazawa; Masaaki Shiohara; Atsushi Manabe; Seiji Kojima; Kenichi Koike
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

5.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.

Authors:  Tetsuya Niihori; Yoko Aoki; Yoko Narumi; Giovanni Neri; Hélène Cavé; Alain Verloes; Nobuhiko Okamoto; Raoul C M Hennekam; Gabriele Gillessen-Kaesbach; Dagmar Wieczorek; Maria Ines Kavamura; Kenji Kurosawa; Hirofumi Ohashi; Louise Wilson; Delphine Heron; Dominique Bonneau; Giuseppina Corona; Tadashi Kaname; Kenji Naritomi; Clarisse Baumann; Naomichi Matsumoto; Kumi Kato; Shigeo Kure; Yoichi Matsubara
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

6.  Germline gain-of-function mutations in RAF1 cause Noonan syndrome.

Authors:  M Abdur Razzaque; Tsutomu Nishizawa; Yuta Komoike; Hisato Yagi; Michiko Furutani; Ryunosuke Amo; Mitsuhiro Kamisago; Kazuo Momma; Hiroshi Katayama; Masao Nakagawa; Yuko Fujiwara; Masaki Matsushima; Katsumi Mizuno; Mika Tokuyama; Hamao Hirota; Jun Muneuchi; Toru Higashinakagawa; Rumiko Matsuoka
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

7.  Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

Authors:  Claudio Carta; Francesca Pantaleoni; Gianfranco Bocchinfuso; Lorenzo Stella; Isabella Vasta; Anna Sarkozy; Cristina Digilio; Antonio Palleschi; Antonio Pizzuti; Paola Grammatico; Giuseppe Zampino; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2006-05-01       Impact factor: 11.025

8.  SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth.

Authors:  Mara Fornaro; Peter M Burch; Wentian Yang; Lei Zhang; Claire E Hamilton; Jung H Kim; Benjamin G Neel; Anton M Bennett
Journal:  J Cell Biol       Date:  2006-10-02       Impact factor: 10.539

9.  Germline mutations in HRAS proto-oncogene cause Costello syndrome.

Authors:  Yoko Aoki; Tetsuya Niihori; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Yukichi Tanaka; Mirella Filocamo; Kumi Kato; Yoichi Suzuki; Shigeo Kure; Yoichi Matsubara
Journal:  Nat Genet       Date:  2005-09-18       Impact factor: 38.330

10.  Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.

Authors:  Marco Tartaglia; Len A Pennacchio; Chen Zhao; Kamlesh K Yadav; Valentina Fodale; Anna Sarkozy; Bhaswati Pandit; Kimihiko Oishi; Simone Martinelli; Wendy Schackwitz; Anna Ustaszewska; Joel Martin; James Bristow; Claudio Carta; Francesca Lepri; Cinzia Neri; Isabella Vasta; Kate Gibson; Cynthia J Curry; Juan Pedro López Siguero; Maria Cristina Digilio; Giuseppe Zampino; Bruno Dallapiccola; Dafna Bar-Sagi; Bruce D Gelb
Journal:  Nat Genet       Date:  2006-12-13       Impact factor: 38.330
View more
  46 in total

1.  Molecular basis of juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; C Michael Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

2.  Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.

Authors:  G M T Guilcher; R Moorjani; T H Truong; V A Lewis
Journal:  Bone Marrow Transplant       Date:  2014-12-08       Impact factor: 5.483

3.  Juvenile Myelomonocytic Leukemia: Profile and Outcome.

Authors:  Manisha Agarwal; Amitabh Singh; Vijay Guru; Rachna Seth
Journal:  Indian J Pediatr       Date:  2017-07-29       Impact factor: 1.967

4.  Myelodysplasia in younger adults: outlier or unique molecular entity?

Authors:  David A Sallman; Eric Padron
Journal:  Haematologica       Date:  2017-06       Impact factor: 9.941

5.  Juvenile myelomonocytic leukemia in a 14-month-old boy presenting with acute respiratory failure.

Authors:  M Kourti; E Papathanasiou; A Taparkou
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

6.  Juvenile myelomonocytic leukemia presenting in an infant with a subdural hematoma.

Authors:  William A Lambert; Joseph A DiGiuseppe; Tatiana Lara-Ospina; Markus J Bookland; Jonathan E Martin; David S Hersh
Journal:  Childs Nerv Syst       Date:  2021-01-06       Impact factor: 1.475

7.  Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.

Authors:  Hirozumi Sano; Ryoji Kobayashi; Daisuke Suzuki; Kazue Yasuda; Masanori Nakanishi; Tetsuro Nagashima; Masafumi Yamada; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2012-06-27       Impact factor: 2.490

8.  Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia.

Authors:  Stefan P Tarnawsky; Michihiro Kobayashi; Rebecca J Chan; Mervin C Yoder
Journal:  J Clin Invest       Date:  2017-08-28       Impact factor: 14.808

9.  Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia.

Authors:  Simone Cesaro; Paola De Filippi; Annamaria Di Meglio; Anna Leszl; Svetlana Donska; Ada Zaccaron; Claudia Cagioni; Roberta Galavotti; Cesare Danesino; Fiorenza Aprili; Chiara Cugno; Geertruy te Kronnie; Marco Zecca; Silvia Bresolin
Journal:  Int J Hematol       Date:  2013-12-12       Impact factor: 2.490

10.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Authors:  Mignon L Loh; Debbie S Sakai; Christian Flotho; Michelle Kang; Manfred Fliegauf; Sophie Archambeault; Charles G Mullighan; Leslie Chen; Eva Bergstraesser; Carlos E Bueso-Ramos; Peter D Emanuel; Henrik Hasle; Jean-Pierre Issa; Marry M van den Heuvel-Eibrink; Franco Locatelli; Jan Stary; Monica Trebo; Marcin Wlodarski; Marco Zecca; Kevin M Shannon; Charlotte M Niemeyer
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.